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Abstract
As  a  comorbid  condition  of  sickle  cell  disease  (SCD),  asthma  leads  to  increased
complications and mortality. However, poor understanding of asthma phenotypes in
SCD and the complex interaction with SCD-related airway inflammation, manifested
by  bronchial  hyperresponsiveness  or  obstructive  airway,  pose  a  unique  clinical
challenge.  The objective of this chapter is  to provide a comprehensive review and
discussion of epidemiology, pathophysiology, interactions, and clinical implications of
airway hyperresponsiveness (AHR), obstructive airway, and asthma in SCD. Discussion
will cover new understanding and limitations of asthma diagnosis and management in
SCD. AHR, lower obstructive airway, and asthma are highly prevalent in SCD. Despite
overlapping features, these entities are nonetheless distinct as demonstrated by basic
science  and  clinical  data.  Diagnosis  of  asthma  should  be  based  on  a  physician
assessment. We provide new unpublished data of a prospective study on diagnosing
asthma in a  small  preschool  population.  Administered validated asthma-screening
questionnaire to SCD children reveals good sensitivity and specificity as an asthma
detection tool. It is unclear at this time if detection of bronchial lability or asthma early
in  life  would result  in  better  outcome of  patients,  or  if  improved control  of  SCD
attenuates lower airway pathology. Being able to distinguish asthma from bronchial
lability in the preschool age children would allow for appropriate intervention early in
life.
Keywords: sickle cell disease, children, pediatrics, asthma, obstructive airway, lower
airway obstruction, wheezing, hyperresponsive airway, hyperreactive airway, reactive
airway disease
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1. Introduction
Asthma is a heterogeneous chronic airway disease seen in 10% of children, characterized by
airway hyperresponsiveness (AHR) and recurrent episodes of airway obstruction due to airway
inflammation.  In  the  general  population,  a  physician diagnosis  of  asthma supported by
pulmonary function testing or laboratory evidence is often sufficient to make such a diagnosis,
but continues to remain an elusive topic in sickle cell disease (SCD).
As a comorbid condition of SCD, asthma may lead to increased complications and mortality.
Children with SCD experience frequent concurrent wheezing, respiratory complications such
as pneumonia or acute chest syndrome (ACS), airway hyper-responsiveness, and airway
obstruction, attributed to SCD-related airway inflammation but not necessarily from asthma.
As a result, wheezing (clinical surrogate for bronchial hyperresponsiveness), obstructive
airway, and asthma are present in higher prevalence within the SCD population, with
significant overlap (Figure 1), rendering common office procedures such as spirometry
(measure of airway obstruction), methacholine challenge testing (measure of hyperrespon-
siveness), and exhaled nitric oxide (measure of asthma-related airway inflammation) inade-
quate to distinguish them apart.
Figure 1. The relationship of asthma, wheezing, and lower airway obstruction in SCD.
2. Pathophysiology (interrelationship between wheezing, asthma,
and obstruction)
The mechanism by which wheezing, obstruction, and asthma develop in SCD is poorly
understood. Transgenic SCD mice demonstrate higher airway resistance via an altered
immunologic pulmonary response, priming the lungs to increased inflammation, and airway
hyperresponsiveness after sensitization to allergens [1]. Therefore, as an inflammatory
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comorbid condition, asthma likely contributes to sickle hemoglobin-induced vasculopathy
and in reverse, SCD attributes to airway inflammation leading to development of asthma,
obstruction, or bronchial hyperresponsiveness (Figure 2). How SCD subtypes variably
influence the lower airways is not adequately described.
Figure 2. Interrelationship of SCD inflammation with lower airway inflammation.
Severe airway narrowing may lead to local hypoxia, promote sickling and systemic inflam-
mation which in turn may increase airway inflammation.
2.1. Lower airway obstruction in SCD
SCD mice compared with hemoglobin A mice possess greater resistance in the airways at
baseline and after allergen challenge [1]. Reversal of SCD-related inflammation through bone
marrow transplant and hydroxyurea lead to improved pulmonary function, implying SCD
adversely affects the lower airways. The effect of SCD on the lower airways starts early in life.
Predominant lower airway obstruction (LAO) abnormality is already present in early infancy,
even prior to a diagnosis of asthma [2]. Majority of older children and adolescents with SCD
have either normal pattern of lung function or lower airway obstruction (LAO). Cross-sectional
prevalence of lower airway obstruction estimates it being high in SCD children [3], ranging
from 20 to 50%. Longitudinal studies further elaborate a tendency of lower airway obstruction
development in childhood [4]. SCD LAO is not associated with increased methacholine
sensitivity or eosinophilic inflammation, eluding to airway hyperresponsiveness and asthma,
respectively, being distinct entities from lower airway obstruction. Increasing age, female
gender, history of asthma or wheezing, tobacco smoke exposure, and high lactate dehydro-
genase (LDH) are independent predictors of obstruction [5]. Clinical significance of LAO in
children remains uncertain; however, some reports describe association with increased vaso-
occlusive crisis [6], but not with ACS or mortality. Ongoing SCD-related airway inflammation
eventually leads to LAO, which in turn increases eosinophil and collagen deposition in the
lungs of SCD mice to a greater extent than control mice [1]. Whether an ongoing LAO even-
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tually progresses into asthma remains uncertain, but SCD airway inflammation could have
deleterious effect on asthma control. Clinically differentiating asthma from LAO poses a
challenge, but respiratory symptoms or complications are primarily associated with the
former. As asthma is poorly characterized in SCD, it isn’t clear if a mild asthma evolves to a
more severe form over time and how best to differentiate mild form of asthma from LAO.
Management guidelines currently do not recommend monitoring pulmonary function
routinely in all SCD children unless symptomatic [7].
2.2. Airway hyperresponsiveness in SCD
AHR is a cardinal feature of asthma in children without SCD; however, a high prevalence of
up to 55–75% in the absence of asthma or reactive airway disease symptoms exists in SCD
children, reaffirming that these entities are distinct [8–10]. Younger age, higher serum immu-
noglobulin E (IgE) concentration, eosinophilia, and a higher LDH level were independently
associated with AHR [11]. The pro-inflammatory state of the SCD lung and its contribution to
AHR is not completely understood but Nitric oxide (NO) metabolism dysregulation may
possibly contribute to its etiology, independent of asthma. A lack of relationship between
methacholine-induced AHR and either traditional symptoms or a physician diagnosis of
asthma suggest a potential novel mechanism for AHR in SCD [12]. Clinical significance of AHR
includes increased complications such as ACS and more frequent vaso-occlusive events [13].
The presence of elevated eicosanoids in SCD asthma is not associated with AHR. Hydroxyurea
use may attenuate AHR, though more confirmatory studies are needed. Not enough data are
available on the beneficial effects of bronchodilators or whether asthma anti-inflammatory
controller medication is beneficial in preventing complications.
2.3. Asthma in sickle cell disease
Asthma is a multifactorial disease that manifests in illness as a final combination of heredita-
bility (genetics), triggers (environment), and immunologic alterations that promote hyperres-
ponsiveness of the airway. This entity is diagnosed based on a physician assessment through
the combination of medical history and physical examination.
A familial pattern of inheritance of asthma exists among first-degree relatives of probands with
diagnosis of both SCD and asthma, suggesting that asthma is a distinct comorbid condition
with SCD rather than a lung disease phenotype mimicking asthma [14]. Autopsy lung
histological findings of a deceased SCD patient with asthma during an acute respiratory event
are consistent with characteristic features of bronchial asthma. Pain crisis and ACS rates were
increased in SCD children without a diagnosis of asthma but with a positive family history of
asthma, compared with children without asthma and a negative family history. When adjusted
to a diagnosis of asthma, individuals with family history of asthma had increased complica-
tions compared to those with asthma but without a family atopic risk [15]. Inflammatory genes
and their corresponding mediators of asthma pathogenesis may therefore contribute to
vascular inflammation.
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Inflammatory mediators implicated in the pathogenesis of asthma and pain provide additional
evidence suggesting that there is a common mechanism between asthma and SCD. Phospho-
lipase A2 activity on cell membrane component arachidonic acid leads to production of
leukotriene products (LTB4, LTC4, LT D4, and CysLT) which in the lungs have effects on
asthma pathogenesis and neutrophil activation (Figure 3). Baseline levels of leukotrienes were
significantly elevated in those with SCD compared to healthy population. Among children
with SCD, levels were higher in those with asthma than those without asthma [16]. Leukotriene
significantly increases during pain crisis or acute chest syndrome in children with sickle cell
disease [17, 18]. Although LTB4 levels have a lesser role in the process of asthma, their actions
on the activation, migration, and adhesion of neutrophils to the endothelium suggest that LTB4
could contribute to the process of vaso-occlusion. In one study, the T-lymphocyte helper cell
cytokine, interleukin (IL)-4, elevation was associated with SCD rather than asthma status [19].
Consistent with SCD-triggered inflammation leading to airway changes, we previously
reported preliminary data of neutrophilia and eosinophilia systemic inflammation, inversely
associated with pulmonary function in asymptomatic asthmatic SCD children [20].
Figure 3. Eicosanoid metabolism and leukotriene biosynthesis.
Histologic findings in sickle cell mice indicate SCD independently induces a baseline lung
pathology that increases large and small airway resistance and primes the lungs to increased
inflammation and airway hyperresponsiveness post- sensitization. Individuals with SCD may
therefore have a unique, divergent phenotype, perhaps amenable to a different therapeutic
approach. Among children in the general population, an elevated IgE level and aeroallergen
sensitization are among the strongest risk factors for asthma. Earlier reports of elevated IgE
[21] and allergen-specific IgE [22] in physician-diagnosed asthma in SCD children were not
replicated subsequently. Aeroallergen sensitization in physician-diagnosed asthma SCD
children was significantly higher than the non-asthma group but was of limited clinical value
in detection of asthma [23].
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Asthma disproportionately affects African-American children in the United States with a
prevalence of about 20%. The prevalence of comorbid asthma in patients with SCD has not
been well defined, as such studies require simultaneous surveillance in the general population.
In children with SCD, estimates of asthma prevalence are similar to that in children of African
descent as in the general population. It is not certain if SCD imparts a modest tendency to
develop asthma. Without a clear definition of asthma or understanding of asthma phenotype
in SCD, the epidemiological data may vary widely. It is well described that a physician’s
diagnosis of asthma is not synonymous with LAO or AHR, and the prevalence of asthma in
multiple SCD cohorts is much lower than LAO and AHR.
Available additional tests include spirometry, methacholine challenge, and exhaled nitric
oxide, for school-aged children provide additional objective measurements to support the
physician’s assessment to make a diagnosis of asthma in children. Potentially, signs and
symptoms suggestive of asthma, such as wheezing or an obstructive pattern on pulmonary
function testing, may be related to pulmonary manifestations of SCD and thus represent a
different pathophysiology than asthma. A high incidence of abnormal pulmonary function
findings, including LAO or a restrictive pattern in the SCD population limit its use in the
diagnosis of asthma. Bronchodilatory effect of beta agonists was appreciated in many non-
asthma SCD patients [3]. Similarly for AHR in SCD, methacholine challenge is unable to
differentiate those who have asthma from those without [12]. Due to dysregulation of the
arginine-NO metabolic pathway in SCD, fractional exhaled nitric oxide (FeNO) levels used to
assess airway eosinophilia activity could be compromised. Recently, it was shown that FeNO
measures were not significantly different in SCD children with a physician diagnosis of asthma
from those without asthma [23].
SCD mice with experimentally induced asthma are more susceptible to death and pulmonary
inflammation compared with control mice, suggesting that asthma contributes significantly to
morbidity and mortality in SCD. In children with both SCD and asthma, respiratory symptoms
are a risk factor for painful episodes. Several clinical studies have since confirmed that
concomitant asthma increases SCD complications of vaso-occlusive events, ACS, pneumonia,
and even mortality [24–27]. Children were diagnosed as asthmatic prior to onset of their first
ACS episode, suggesting that asthma exacerbations may predispose to ACS episodes. Mech-
anisms by which asthma predisposes to increased morbidity and mortality remain unclear.
3. Physician assessment in asthma diagnosis
To date, all studies defining asthma are based on a physician’s subjective assessment. The
objective criteria used to make a physician diagnosis of asthma are not well defined and may
vary from one physician to another. Whether a physician diagnosis of asthma in children with
SCD has the same constellation of clinical features that are recognized among children without
SCD is not known.
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3.1. Asthma-screening questionnaire in school-aged children with SCD
In 2015, we published data that demonstrated the utility of an asthma-screening questionnaire
to identify physician-diagnosed asthma in SCD children. In this study, we prospectively
administered a previously validated asthma-screening questionnaire to 41 SCD children on a
routine clinic visit. Prevalence of obstructive airway was high at 51.2% and physician diagnosis
of asthma was lower, 33.3%. The sensitivity and specificity were high in detecting physician
diagnosis of asthma in this SCD population [28].
An asthma-screening questionnaire showed to be a useful tool in identifying at-risk SCD
children who may benefit from further asthma management as an effective, easy-to-administer
screening tool. More importantly, as the screening questionnaire had been developed and
validated in the general population, it provided new evidence that a physician diagnosis of
asthma in children with and without SCD was consistent. In another study, after extensive
evaluation of SCD children for respiratory symptomology, atopic risk, pulmonary function
measures, and inflammatory markers; parental history of asthma, wheezing causing shortness
of breath, and wheezing after exercise were predictive of development of asthma [23],
indicating the importance of a proper history and physical in determining an asthma diagnosis.
We did not observe a difference between parental history of asthma in SCD with the asthma
and non-asthma groups, but allergic rhinitis was significantly seen in the asthma group.
3.2. Wheezing and SCD
Children with SCD are more likely to wheeze than non-SCD children in the same geographical
setting [29]. Wheezing likely is a clinical surrogate of SCD inflammation-related AHR,
bronchial asthma airway inflammation, or both. No age association between wheezing and
asthma diagnosis exists; therefore, children with wheezing were no more likely to carry an
asthma diagnosis than adults [30]. Some SCD patients have recurrent wheezing without a
personal or familial history of asthma. Risk factors including upper respiratory tract infection,
environmental tobacco smoke exposure, maternal history of asthma, lower socioeconomic
status, excessive production of inflammatory mediators such as leukotrienes, low vitamin D
level, and exposure to acetaminophen in early life were found to be associated with wheezing
independent of asthma [30]. Many of these risk factors are similar to early life wheezing in the
general population and asthma. The International Study of Asthma and Allergies in Childhood
(ISAAC) to assess current respiratory symptoms of asthma showed that recent use of acet-
aminophen was associated with an exposure-dependent increased risk of asthma [31];
therefore, further work is needed in SCD due to high exposure of pain medications. Recurrent,
severe wheezing regardless of asthma status was associated with increased pain crisis, ACS,
and mortality. Wheezing and asthma are likely independent risk factors of SCD complications
[32].
The Asthma Predictive Index (API) was developed for children less than 3 years old with
recurrent wheezing. This index was created as a guide for the primary physician to determine
which children would likely have asthma later in life. The API takes into consideration a
combination of major and minor criteria (Table 1) to evaluate the patient asthma risk.
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Major criteria Minor criteria
Parental asthma Food allergies
Physician diagnosis of atopic dermatitis Eosinophilia >4%
Sensitization to aeroallergens Wheezing apart from colds
Table 1. Asthma predictive index: a positive API requires ≥3 episodes of wheezing a year during the first 3 years of age
and one of the two major criteria or two of the three minor criteria.
In preschool children aged 3–5 years, or younger, the diagnosis of asthma sometimes is a
challenge. Many times, viral respiratory illnesses may mimic early asthma symptoms. Cardinal
symptoms that suggest asthma include dry cough, trouble in breathing, chest tightness or pain,
and wheezing, most of them are also present in SCD. Asthma could be exacerbated by weather
changes, colds, emotions, or exercise. In SCD patients, diagnosis of asthma may be even harder
taking into consideration the vaso-occlusive pathophysiology involved in this disease as an
additional confounding factor for asthma symptoms. It is uncertain if the API can be reliably
applied to the SCD population.
3.3. Asthma in the preschool SCD population
For a primary physician, diagnosis of asthma in the preschool population may be a potential
challenge notwithstanding other several comorbidities that can mask asthma symptoms like
in those patients with SCD.
In our unpublished 3-years prospective study, a validated asthma-screening questionnaire was
administrated to 12 preschool SCD children (aged 2–5 years) on a routine clinic visit. Preva-
lence of physician diagnosis of asthma at initial visit was 33.3% (n = 4). We found that the
abbreviated three-question version had 100% sensitivity and 62.5% specificity in detecting
asthma early in life in this subject population when followed over time. The Breathmobile Case
Identification Survey (BCIS) in preschool-age children in the general population had a high
sensitivity (70%) and specificity (84%) [33]. Further work is required to assess early asthma-
screening approaches in SCD.
These data demonstrate that a validated asthma-screening tool intended for the general
population might be relevant in preschool SCD and might be used as a screening tool for a
valid asthma diagnostic approach. A validated screening tool implemented in early asthma
diagnosis will help the primary physician to assess objectively and uniformly the diagnosis of
asthma in preschool SCD children in order to identify individuals at risk of major complica-
tions or those with poorly controlled asthma.
It is unclear if detection of bronchial lability or asthma diagnosis earlier would result in better
outcomes or if improved asthma control in SCD attenuates lower airway pathology. Identifying
mild asthma would continue to remain a challenge. Previously, due to poor understanding of
an asthma diagnosis in this high-risk population, clinical trials were difficult to conduct,
resulting in a gap of knowledge. Future research to evaluate the impact of early asthma
detection in the development of further comorbidities in SCD children should be explored.
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4. Asthma management in SCD
Sickle cell disease is marked by high utilization of medical services. A history of asthma was
associated with an increased risk of SCD emergency department (ED) utilization for both pain
and ACS [34]. Recently, the patient-centered medical home (PCMH) emerged as a viable
method to improve delivery of medical care. The American Academy of Pediatrics (AAP)
currently defines a PCMH as care that is accessible, continuous, comprehensive, family-
centered, coordinated, compassionate, and culturally effective. Children with SCD reported
to experience comprehensive care had lower rates of ED encounters and hospitalizations after
controlling for demographics and health status. SCD patients with asthma are anticipated to
benefit the most in this setting.
Achievement of asthma control to reduce pulmonary complications and mortality are the goals
of the National Asthma Education and Prevention Program (NAEPP) expert panel report 3 on
2007 guidelines. These guidelines focus on impairment and risk as key factors to assess asthma
severity and control. Treatment recommendations are summarized in a stepwise approach for
long-term asthma treatment taking into consideration the patient age and epidemiologic risk
factors. Currently, physicians follow the NAEPP 2007 asthma guidelines in order to minimize
future comorbidities and reduce asthma-related mortality in the pediatric population.
It is known that the pathophysiology of asthma involves several overlapping areas that affect
the asthma phenotype in each patient. Also many comorbid factors can play a direct role in
the development of asthma, SCD being one of them. Concerns regarding asthma management
in SCD using the standard NAEPP 2007 approach have arisen, taking in consideration the
hemolytic and chronic inflammatory state of this disease. Current consensus in the manage-
ment of asthma in SCD agrees with the use of NAEPP 2007 guidelines to treat SCD asthma
until new studies demonstrate a different approach.
Acute asthma exacerbations
• Rescue medications may include inhaled bronchodilators (albuterol and ipratropium) and
systemic corticosteroids.
• Several cases have been described associating oral corticosteroid use with rebound pain and
ACS. However, their use should not be withheld in the setting of an acute asthma exacer-
bation. A slow taper of systemic corticosteroids may decrease the risk for rebound pain.
• Admit all patients with acute asthma exacerbations requiring corticosteroids and consider
a lower threshold to admit SCD patients with mild asthma exacerbations in view of the
potential complications, such as ACS or pain crisis.
Long-term asthma control
• Physicians are encouraged to prescribe inhaled corticosteroids (ICS) as the first line for
asthma-controlled medication and to consider additional controlled medications such as
leukotriene inhibitors.
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• Consult pulmonary specialist and hematologist when starting ICS in an SCD patient.
• Interval pulmonary function test in the outpatient setting is recommended.
• Asthma assessment on all SCD patients at least annually.
• A Doppler echocardiogram annually in SCD patient with asthma to screen for pulmonary
hypertension.
• A baseline EKG should be completed before starting therapy with beta2 agonists due to
increased risk of prolonged QTc complications in SCD.
In the following sections, we expand the available literature on asthma management in the
SCD population and explore future areas of interest about this topic [35].
4.1. Oxygen therapy
As part of the management of acute asthma exacerbations in the general population, oxygen
therapy plays an important role in the correction of asthma-induced hypoxemia, secondary to
V/Q mismatch. In SCD, oxygen is also part of the initial management for acute chest syndrome.
It is known that in SCD, the onset of erythrocyte sickling can be triggered by hypoxemia and,
for instance, the development of acute chest syndrome. More studies are needed to evaluate
the benefit of oxygen in SCD in the acute setting of asthma. Short-term oxygen in an acute
asthma exacerbation should be initiated with SCD during a moderate to severe asthma
exacerbation.
4.2. Bronchodilators
Acute hyper-responsiveness can be treated successfully with short-term inhaled bronchodi-
lators that selectively stimulate the Beta-2 receptors in the airway and relax the smooth muscle.
In SCD, the approach may be different if acute chest syndrome overlaps with an acute asthma
exacerbation. On red blood cells, beta2-receptor stimulation was associated with cellular
adhesion in vivo. This may theoretically promote vaso-occlusive episodes in SCD but clinically
this phenomenon has not been described. Studies to evaluate the effectiveness in the treatment
of asthma and acute chest syndrome in SCD have not been performed. Several Cochrane
Reviews have shown consistently the lack of well-designed randomized controlled trials in
this area. As a clinician, this information will be helpful to evaluate the risks of the use of
inhaled bronchodilators in the therapy for acute chest syndrome and asthma in the SCD
population [36].
Inhaled beta2 agonist has been related with life-threatening cardiac events in adults with long
QT syndrome [37]. Prolonged QTc is a frequent finding in the SCD pediatric and young adult
population. Considering this, evaluation for possible life-threatening events in SCD related to
QTc prolongation after beta2 agonist use may be warranted [38]. An EKG prior to starting a
beta2 agonist will provide useful information at initial evaluation in SCD asthma management
to prevent additional comorbidities. A randomized control trial evaluating the risk of the use
of beta2 agonists in SCD secondary to QTc prolongation needs to be explored.
Sickle Cell Disease - Pain and Common Chronic Complications162
Long-term bronchodilators (long-acting beta-agonists [LABAs]) are recommended for asthma
control in those with moderate to severe persistent asthma as per NAEPP 2007 guidelines. In
SCD, some concerns arise about the use considering the epidemiology of the disease. In the
Salmeterol Multicenter Research Trial (SMART), African-American subgroup showed an
increased risk for respiratory-related deaths [39], prompting the US Food and Drug Admin-
istration (USFDA) to issue a black box warning. The safety profile of LABA is currently being
investigated in the pediatric population with the VRESTRI clinical trial and is expected to
complete in 2017.
An alternative approach to address the risk of short-acting beta-agonists (SABA or LABA) use
in the African-American SCD population for asthma management is the use of short-acting
and long-acting anticholinergics. Ipratropium and tiotropium work as acetylcholine receptor
antagonists, causing bronchodilation. A randomized clinical trial in 2015 has compared the
effectiveness and safety of tiotropium versus LABAs. In this study, African-American adults
with moderate to severe asthma were enrolled over 18 months. The combination of LABAs or
tiotropium with ICS showed no significant differences in asthma exacerbations, forced
expiratory volume in 1 s (FEV1), asthma control questionnaire (ACQ) scores, or patient
reported outcomes [40].
An observational study evaluated the increased pulmonary capillary volume as a possible
explanation for airway obstruction in SCD patients. They found that an increased pulmonary
capillary volume contributes to increased airway obstruction and, for instance, may limit the
effect of ipratropium in reducing airway obstruction in SCD [41].
4.3. Leukotriene’s inhibitors
During acute asthma episodes, prolific release of inflammatory metabolites contributes to
airway bronchoconstriction and acute exacerbations. Leukotrienes are arachidonic acid
metabolites that contribute to airway inflammation in asthma and may have additional
pathophysiologic roles in SCD. Lung leukotriene cascade activates and releases additional
metabolites including LTA4, LTB4, LTC4, LTD4, and LTE4 after activation of the 5-lipoxygenase,
a key enzyme in the biosynthesis of leukotrienes (Figure 3).
Montelukast is an adjuvant therapy that works as a leukotriene receptor antagonist (LTRA) in
the airway mast cells, eosinophils, and also in lung epithelial cells. Of all LTRAs, LTD4 is the
most potent bronchoconstrictive leukotriene. Additional chemo-attractive properties have
been attributed to Cyst-LTs with a direct effect on lung vascular permeability, mucous
secretion, and airway narrowing. Currently, under recruitment process, a phase-2 clinical trial
tries to evaluate the effect of montelukast as an adjuvant medication to hydroxyurea for SCD
vaso-occlusion treatment. This trial will provide valuable information about the role of
leukotrienes in the SCD inflammatory state. Additional studies are needed to evaluate efficacy
of LTRA inhibitors in SCD and asthma.
Zileuton is a specific 5-lipoxygenase inhibitor with a direct activity by decreasing leukotriene
production. It is suggested that zileuton could have benefits in SCD considering the structural
analog of hydroxyurea, and the advantage of inducing fetal hemoglobin to improve oxygen
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affinity and delivery. In vitro trials have documented a potential effect in downregulating SCD
inflammatory state through nitric oxide pathways in a dose-dependent effect [42]. Upregula-
tion of IL-13 with hydroxyurea and downregulation of IL-13 with zileuton has been docu-
mented in vitro. This observation promotes the idea that zileuton is a potential drug for
management of the SCD inflammatory state [43]. A phase-I trial evaluated the role and tested
the safety of zileuton to reduce inflammation associated with SCD in a dose-dependent manner
in children and adults [44]. Phase-II and -III clinical trials are pending to be done to explore
the interactions between zileuton and hydroxyurea in SCD.
4.4. Corticosteroid
As per NAEPP 2007 guidelines, moderate to severe persistent asthma involves the introduction
of an inhaled corticosteroid in order to achieve asthma control in the pediatric population.
However, unclear data about the use and safety of corticosteroid in SCD children introduce
challenges in the management.
Specific data regarding the use of corticosteroid in the management of asthma are needed.
Some trials have evaluated systemic corticosteroids in the setting of acute chest syndrome in
SCD. In a randomized trial evaluating the efficacy of dexamethasone in SCD with acute chest
syndrome a beneficial effect was found [45]. Significant statistical data showed lower rates of
hospitalizations, blood transfusions, duration of oxygen and analgesic medications; however,
the subjects were never evaluated for pre-existing asthma diagnosis. Noteworthy here is that
the rebound readmission rate in the dexamethasone group has raised some concern.
Rebound pain crisis after systemic corticosteroid use had been a concern in SCD. The potent
anti-inflammatory effects of systemic corticosteroid may have a role in the management of
ACS and asthma. Nevertheless, rebound pain and subsequent readmission may limit their use
to an SCD sub-population [46]. It is suggested to use a longer course of systemic steroid with
slow taper, but controlled clinical trials would be needed to evaluate this approach.
It is currently recommended to follow NAEPP 2007 guidelines as part of the treatment of
asthma in SCD. Systemic steroid may be used in moderate to severe asthma exacerbations
with a close monitoring for rebound pain. An individual approach may be considered to
start inhaled corticosteroids in persistent asthma in SCD to avoid asthma-related morbidity,
while upcoming clinical trials provide the clinician evidence-based guidelines about the
best strategies for asthma management in SCD. However, poor understanding of asthma
phenotype in SCD and additive bronchial asthma airway inflammation to underlying SCD
inflammation, and its impact on asthma control has not been explored. Current clinical tri-
als for inhaled mometasone and budesonide are being conducted to address the gap in the
knowledge.
4.5. New therapy in asthma
New modes of asthma management may have beneficial effects on SCD asthma airway
inflammation and asthma. However, no data are currently available on these modes of therapy.
These include immunotherapy, monoclonal antibody against specific immune protein, and
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bronchial thermoplasty. The role of hydroxyurea and other anti-inflammatory interventions
of SCD in improving asthma control requires investigation.
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